Indaptus Therapeutics Says Health Canada Approves Start of Lead Asset Decoy20 Trial

MT Newswires Live

2025/02/05

Indaptus Therapeutics (INDP) said Wednesday it received clinical trial authorization from Health Canada for its Decoy20 drug candidate.

The approval allows expansion of the company's ongoing US phase 1 study, INDP-D101, in patients with locally advanced or metastatic solid tumors to Canadian sites, according to Indaptus.

The company said it will enroll patients in Canada under the current protocol of weekly dosing of Decoy20. Indaptus plans to amend the Health Canada submission to include its upcoming Decoy20 and BeiGene's tislelizumab combination trial.

Shares of the company were down 1.3% in recent trading.

Price: 0.89, Change: -0.01, Percent Change: -1.33

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2509533233"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509533233\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2509533233?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-05 23:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509533233","market":"nz","top_or_hot":-1,"title":"Indaptus Therapeutics Says Health Canada Approves Start of Lead Asset Decoy20 Trial","media":"MT Newswires Live","content":"<html><body><p> Indaptus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (INDP) said Wednesday it received clinical trial authorization from Health Canada for its Decoy20 drug candidate.</p><p>The approval allows expansion of the company's ongoing US phase 1 study, INDP-D101, in patients with locally advanced or metastatic solid tumors to Canadian sites, according to Indaptus.</p><p>The company said it will enroll patients in Canada under the current protocol of weekly dosing of Decoy20. Indaptus plans to amend the Health Canada submission to include its upcoming Decoy20 and BeiGene's tislelizumab combination trial.</p><p>Shares of the company were down 1.3% in recent trading.</p><p>Price: 0.89, Change: -0.01, Percent Change: -1.33</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Indaptus Therapeutics Says Health Canada Approves Start of Lead Asset Decoy20 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndaptus Therapeutics Says Health Canada Approves Start of Lead Asset Decoy20 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-05 23:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Indaptus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (INDP) said Wednesday it received clinical trial authorization from Health Canada for its Decoy20 drug candidate.</p><p>The approval allows expansion of the company's ongoing US phase 1 study, INDP-D101, in patients with locally advanced or metastatic solid tumors to Canadian sites, according to Indaptus.</p><p>The company said it will enroll patients in Canada under the current protocol of weekly dosing of Decoy20. Indaptus plans to amend the Health Canada submission to include its upcoming Decoy20 and BeiGene's tislelizumab combination trial.</p><p>Shares of the company were down 1.3% in recent trading.</p><p>Price: 0.89, Change: -0.01, Percent Change: -1.33</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2509533233","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509533233","pubTimestamp":1738769972,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Indaptus Therapeutics  said Wednesday it received clinical trial authorization from Health Canada for its Decoy20 drug candidate.The approval allows expansion of the company's ongoing US phase 1 study, INDP-D101, in patients with locally advanced or metastatic solid tumors to Canadian sites, according to Indaptus.The company said it will enroll patients in Canada under the current protocol of weekly dosing of Decoy20. Indaptus plans to amend the Health Canada submission to include its upcoming Decoy20 and BeiGene's tislelizumab combination trial.Shares of the company were down 1.3% in recent trading.Price: 0.89, Change: -0.01, Percent Change: -1.33","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","INDP":"Indaptus Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Indaptus Therapeutics表示加拿大卫生部批准开始主要资产Decoy20试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"INDP":0.9},"content_text":"Indaptus Therapeutics (INDP) said Wednesday it received clinical trial authorization from Health Canada for its Decoy20 drug candidate.The approval allows expansion of the company's ongoing US phase 1 study, INDP-D101, in patients with locally advanced or metastatic solid tumors to Canadian sites, according to Indaptus.The company said it will enroll patients in Canada under the current protocol of weekly dosing of Decoy20. Indaptus plans to amend the Health Canada submission to include its upcoming Decoy20 and BeiGene's tislelizumab combination trial.Shares of the company were down 1.3% in recent trading.Price: 0.89, Change: -0.01, Percent Change: -1.33","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}